Related Experiment Video
Updated: Jul 14, 2026
07:08
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Palliative care provision in Huntington's disease
Elizabeth Travers1, Kate Jones, Jacqueline Nichol
1Marie Curie Cancer Centre, Marie Curie Hospice, Glasgow. Liz.Travers@mariecurie.org.uk
International Journal of Palliative Nursing
|May 17, 2007
Summary
Palliative care access varies for non-malignant diseases. Huntington's disease (HD) patients and families face unique challenges in accessing and providing palliative care due to the condition's long duration and impact.
Area of Science:
- Palliative Care
- Neurology
- Quality of Life Research
Background:
- Growing interest in palliative care needs for non-malignant diseases.
- Existing evidence suggests unequal access to palliative care services.
- Some non-malignant conditions, like cardiac and motor neurone disease, have better access than others.
Purpose of the Study:
- To review the relationship between Huntington's disease (HD) and palliative care.
- To discuss challenges in implementing palliative care for HD patients and families.
- To highlight the importance of understanding HD for effective care provision.
Main Methods:
- Literature review on Huntington's disease and palliative care.
- Analysis of challenges in palliative care adoption for chronic neurological conditions.
- Discussion of patient, family, and healthcare professional perspectives.
Main Results:
- Huntington's disease (HD) presents a lengthy palliative phase due to its progressive nature.
- Diagnosis significantly impacts the quality of life for individuals with HD and their families.
- Caregivers require comprehensive understanding of HD for effective support.
Conclusions:
- Palliative care integration for Huntington's disease (HD) is complex.
- Addressing the specific needs of HD patients and families is crucial for improving care.
- Further strategies are needed to overcome barriers to palliative care in HD management.
Related Concept Videos
01:25Continuing Care
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:26Peripheral Artery Disease IV: Nursing Management
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...